Anti KL-6 antibody enhances the effects of molecular targeted drug

2013 Fiscal Year Final Research Report

• Project/Area Number: 23659433
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: Respiratory organ internal medicine
• Research Institution: Hiroshima University
• Principal Investigator: KOHNO Nobuoki 広島大学, 医歯薬保健学研究院(医), 教授 (80215194)
• Co-Investigator(Renkei-kenkyūsha): HATTORI Noboru 広島大学, 医歯薬保健学研究院(医), 准教授 (00283169) ; ISHIKAWA Nobuhisa 広島大学, 医歯薬保健学研究院(医), 講師 (90423368)
• Project Period (FY): 2011 – 2013
• Keywords: KL-6 / 分子標的治療薬 / 肺癌

Research Abstract

The aim of the present study was to investigate the additive effect of anti-KL-6 antibody on the therapeutic antibody-induced ADCC (Antibody-Dependent Cellular-Cytotoxicity) activity. The expression of HER2 and KL-6 were measured using FACS analysis in 4 cancer cell lines (SK-BR-3, ZR75-1, PC3, YMB-S), and both HER2 and KL-6 were highly expressed in YMB-S cells. Accordingly, the effects of anti KL-6 antibody on the ADCC activity of PBMCs evoked by Trastuzumab were examined using Cr-51 release assay. Enhanced cytotoxicity was observed in an effector-to-target ratio manner when YMB-S cells were treated with anti-KL-6 antibody. These findings indicate that anti KL-6 antibody can enhance the therapeutic antibody-induced ADCC activity mediated by mononuclear cells.

Research Products

• [Journal Article] SK-216, an inhibitor of plasminogen activator inhibitor-1, limits tumor progression and angiogenesis (2013)
  • Author(s): Masuda T, Hattori N, Senoo T, Akita S, Ishikawa N, Fujitaka K, Haruta Y, Murai H, Kohno N
  • Journal Title: Mol Cancer Ther Volume: 12 Pages: 2378-88
  • DOI: 10.1158/1535-7163.
  • Peer Reviewed
• [Journal Article] Krebs von den Lungen-6 (KL-6) is a prognostic biomarker in patients with surgically resected nonsmall cell lung cancer (2012)
  • Author(s): Tanaka S, Hattori N, Ishikawa N, Shoda H, Takano A, Nishino R, Okada M, Arihiro K, Inai K, Hamada H, Yokoyama A, Kohno N
  • Journal Title: Int J Cancer Volume: 15 Pages: 130:377-87
  • DOI: 10.1002/ijc.26007.
  • Peer Reviewed
• [Journal Article] Interferon (alpha, beta and omega) receptor 2 is a prognostic biomarker for lung cancer (2012)
  • Author(s): Tanaka S, Hattori N, Ishikawa N, Horimasu Y, Deguchi N, Takano A, Tomoda Y, Yoshioka K, Fujitaka K, Arihiro K, Okada M, Yokoyama A, Kohno N
  • Journal Title: Pathobiology Volume: 79 Pages: 24-33
  • DOI: 10.1159/000331230.
  • Peer Reviewed
• [Presentation] Antitumor effect of a humanized antibody against aminopeptidase N in mouse tumor models (2013)
  • Author(s): Akita S, Hattori N, Ishikawa N, Fujitaka K, Haruta Y, Murai H, Kohno N
  • Organizer: 18th congress of the Asian Pacific Society of Respirology
  • Place of Presentation: 横浜
  • Year and Date: 2013-11-11
• [Presentation] Discovery and clinical application of KL-6, a circulating biomarker for interstitial lung diseases (2013)
  • Author(s): Kohno N
  • Organizer: 2013 European Respiratory Society Annual Congress
  • Place of Presentation: Barcelona Spain
  • Year and Date: 2013-09-07
• [Presentation] Krebs von den Lungen-6 (KL-6) is a prognostic biomarker in patients with surgically resected nonsmall cell lung cancer (2011)
  • Author(s): Tanaka S, Ishikawa N, Hattori N, Hamada H, Yokoyama A, Kohno N
  • Organizer: 2011 European Respiratory Society Annual Congress
  • Place of Presentation: Amsterdam, Netherlands
  • Year and Date: 2011-09-24